Arcutis Biotherapeutics (ARQT) Earnings Analysis
Arcutis Biotherapeutics (ARQT) has no confirmed upcoming earnings date. Last quarter (2026-02-25) it beat with EPS 0.13 USD vs 0.03 USD est (+333.3%). It has beaten estimates in 2/2 recent quarters (100%). Trailing P/E -1453.13.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ARQT next report earnings?
No confirmed upcoming earnings date is currently scheduled for ARQT. This page updates as the calendar is published.
ARQT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-25 | 0.13 USD | 0.03 USD | +333.3% | Beat |
| 2024-08-14 | -0.42 USD | -0.48 USD | +12.5% | Beat |
Beat rate: 2/2 (100%) over reported quarters with consensus data.
ARQT valuation and analyst view
| Trailing P/E | -1453.13 |
|---|---|
| Trailing EPS | -0.01837 USD |
| Price / book | 19.03 |
| Dividend yield | 0.00% |
| Market cap | 3.48B |
| Analyst consensus | Buy (10 buy / 2 hold / 0 sell) |
| Avg price target | 32.4 USD |
Related research pages
Frequently asked questions
When is Arcutis Biotherapeutics (ARQT)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ARQT. This page updates as the calendar is published.
Did ARQT beat earnings last quarter?
In its 2026-02-25 report, ARQT posted EPS of 0.13 USD versus a 0.03 USD estimate — a beat of 333.3%.
What is ARQT's earnings track record?
Over the last 2 reported quarters with consensus data, ARQT beat estimates 2 times (100%).
What is ARQT's current P/E ratio and EPS?
ARQT trades at a trailing P/E of -1453.13 on trailing EPS of -0.018366637034746648 USD.
What do analysts rate ARQT?
Analyst consensus is "Buy" across 12 ratings (0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 32.4 USD.